Secondly, immune checkpoint molecules, such as PD-L1 and cytotoxic T-lymphocyte associated protein 4(CTLA4), have been extensively investigated as a cancer therapy, with this immunotherapy notably enhancing the survival rates of patients with certain types of cancer (46). Here, CTLA4 is linked to cancer.